Do analysts rate BYSI or INTS?

Intensity Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 801.44%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Intensity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Is BYSI or INTS more profitable?

BeyondSpring's return on equity of 0.00% beat Intensity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Intensity Therapeutics N/A -136.82% -105.82%

Is ATYR or INTS more profitable?

aTyr Pharma's return on equity of -88.95% beat Intensity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -88.95% -65.31% Intensity Therapeutics N/A -136.82% -105.82%

Does the media prefer ATYR or INTS?

In the previous week, aTyr Pharma had 5 more articles in the media than Intensity Therapeutics. MarketBeat recorded 6 mentions for aTyr Pharma and 1 mentions for Intensity Therapeutics. aTyr Pharma's average media sentiment score of 0.77 beat Intensity Therapeutics' score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to INTS or GOSS?

In the previous week, Intensity Therapeutics and Intensity Therapeutics both had 1 articles in the media. Intensity Therapeutics' average media sentiment score of 0.00 equaled Gossamer Bio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, INTS or EDSA?

Edesa Biotech is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Intensity Therapeutics N/A N/A -$11.61M -$5.71 N/A Edesa Biotech N/A N/A -$7.19M -$1.34 N/A

Is INTS or EDSA more profitable?

Intensity Therapeutics' return on equity of -136.82% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Intensity Therapeutics N/A -136.82% -105.82% Edesa Biotech N/A -286.52% -75.36%

Does the media refer more to INTS or EDSA?

In the previous week, Edesa Biotech had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 2 mentions for Edesa Biotech and 1 mentions for Intensity Therapeutics. Edesa Biotech's average media sentiment score of 0.46 beat Intensity Therapeutics' score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Edesa Biotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MCRB or INTS?

In the previous week, Seres Therapeutics had 10 more articles in the media than Intensity Therapeutics. MarketBeat recorded 11 mentions for Seres Therapeutics and 1 mentions for Intensity Therapeutics. Seres Therapeutics' average media sentiment score of 0.36 beat Intensity Therapeutics' score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Intensity Therapeutics (INTS) Competitors

$4.16 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$4.22 +0.06 (+1.44%)

As of 08/7/2026 06:21 PM Eastern

Compare

INTS vs. BYSI, ATYR, GOSS, EDSA, and MCRB

Should you buy Intensity Therapeutics stock or one of its competitors? MarketBeat compares Intensity Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Intensity Therapeutics include BeyondSpring (BYSI), aTyr Pharma (ATYR), Gossamer Bio (GOSS), Edesa Biotech (EDSA), and Seres Therapeutics (MCRB).

How does Intensity Therapeutics compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Intensity Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 801.44%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

BeyondSpring has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market.

BeyondSpring's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Intensity Therapeutics	N/A	-136.82%	-105.82%

In the previous week, Intensity Therapeutics had 1 more articles in the media than BeyondSpring. MarketBeat recorded 1 mentions for Intensity Therapeutics and 0 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 0.00 equaled Intensity Therapeutics'average media sentiment score.

Company	Overall Sentiment
BeyondSpring	Neutral
Intensity Therapeutics	Neutral

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 7.6% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BeyondSpring has higher revenue and earnings than Intensity Therapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	20.44	-$1.01M	-$0.14	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

Summary

BeyondSpring and Intensity Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Intensity Therapeutics compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

aTyr Pharma's return on equity of -88.95% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-88.95%	-65.31%
Intensity Therapeutics	N/A	-136.82%	-105.82%

In the previous week, aTyr Pharma had 5 more articles in the media than Intensity Therapeutics. MarketBeat recorded 6 mentions for aTyr Pharma and 1 mentions for Intensity Therapeutics. aTyr Pharma's average media sentiment score of 0.77 beat Intensity Therapeutics' score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

aTyr Pharma has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market.

Intensity Therapeutics has lower revenue, but higher earnings than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	263.91	-$74.12M	-$0.62	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

61.7% of aTyr Pharma shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 5.8% of aTyr Pharma shares are held by insiders. Comparatively, 7.6% of Intensity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

aTyr Pharma presently has a consensus price target of $17.00, suggesting a potential upside of 3,224.21%. Intensity Therapeutics has a consensus price target of $37.50, suggesting a potential upside of 801.44%. Given aTyr Pharma's higher probable upside, equities analysts plainly believe aTyr Pharma is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

aTyr Pharma beats Intensity Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Intensity Therapeutics compare to Gossamer Bio?

Intensity Therapeutics (NASDAQ:INTS) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

Intensity Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Intensity Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A
Gossamer Bio	$48.47M	0.86	-$170.37M	-$0.79	N/A

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by insiders. Comparatively, 3.7% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Intensity Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -324.82%. Gossamer Bio's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
Gossamer Bio	-324.82%	N/A	-96.10%

In the previous week, Intensity Therapeutics and Intensity Therapeutics both had 1 articles in the media. Intensity Therapeutics' average media sentiment score of 0.00 equaled Gossamer Bio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gossamer Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Intensity Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 801.44%. Gossamer Bio has a consensus target price of $3.20, suggesting a potential upside of 1,697.75%. Given Gossamer Bio's higher possible upside, analysts plainly believe Gossamer Bio is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Intensity Therapeutics has a beta of 2.76, suggesting that its stock price is 176% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market.

Summary

Gossamer Bio beats Intensity Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Intensity Therapeutics compare to Edesa Biotech?

Intensity Therapeutics (NASDAQ:INTS) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Edesa Biotech is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.34	N/A

Intensity Therapeutics currently has a consensus price target of $37.50, suggesting a potential upside of 801.44%. Edesa Biotech has a consensus price target of $5.00, suggesting a potential downside of 5.12%. Given Intensity Therapeutics' higher possible upside, equities research analysts plainly believe Intensity Therapeutics is more favorable than Edesa Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Edesa Biotech had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 2 mentions for Edesa Biotech and 1 mentions for Intensity Therapeutics. Edesa Biotech's average media sentiment score of 0.46 beat Intensity Therapeutics' score of 0.00 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Edesa Biotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Intensity Therapeutics has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

Intensity Therapeutics' return on equity of -136.82% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-136.82%	-105.82%
Edesa Biotech	N/A	-286.52%	-75.36%

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by company insiders. Comparatively, 24.4% of Edesa Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Edesa Biotech beats Intensity Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Intensity Therapeutics compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Intensity Therapeutics has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Seres Therapeutics' return on equity of -114.82% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Intensity Therapeutics	N/A	-136.82%	-105.82%

Seres Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.76, suggesting that its share price is 176% more volatile than the broader market.

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by company insiders. Comparatively, 7.6% of Intensity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Seres Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 249.08%. Intensity Therapeutics has a consensus target price of $37.50, indicating a potential upside of 801.44%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Seres Therapeutics has higher revenue and earnings than Intensity Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	61.28	$5.70M	-$2.43	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

In the previous week, Seres Therapeutics had 10 more articles in the media than Intensity Therapeutics. MarketBeat recorded 11 mentions for Seres Therapeutics and 1 mentions for Intensity Therapeutics. Seres Therapeutics' average media sentiment score of 0.36 beat Intensity Therapeutics' score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Seres Therapeutics beats Intensity Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Intensity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INTS vs. The Competition

Export

Metric	Intensity Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.23M	$11.85B	$7.00B	$12.99B
Dividend Yield	N/A	2.70%	2.58%	10.20%
P/E Ratio	-0.73	790.97	270.59	25.05
Price / Sales	N/A	739.73	599.45	84.15
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	0.84	10.28	11.21	6.43
Net Income	-$11.61M	$2.78B	$3.45B	$348.10M
7 Day Performance	-2.35%	2.74%	3.41%	2.68%
1 Month Performance	-12.97%	-0.66%	-0.71%	-0.83%
1 Year Performance	-39.49%	192.51%	77.31%	23.97%

Intensity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INTS Intensity Therapeutics	2.1497 of 5 stars	$4.16 flat	$37.50 +801.4%	-39.5%	$11.23M	N/A	N/A	2,021	Upcoming Earnings Gap Up
BYSI BeyondSpring	0.0398 of 5 stars	$1.16 -2.0%	N/A	-56.5%	$48.73M	$1.75M	N/A	80	Upcoming Earnings
ATYR aTyr Pharma	3.8379 of 5 stars	$0.48 -2.2%	$17.00 +3,419.7%	-90.4%	$48.44M	$190K	N/A	53	Earnings Report Gap Down
GOSS Gossamer Bio	2.106 of 5 stars	$0.21 +0.8%	$3.20 +1,448.1%	-89.9%	$48.14M	$48.47M	N/A	180
EDSA Edesa Biotech	1.2273 of 5 stars	$5.36 +7.8%	$5.00 -6.7%	+148.6%	$47.88M	N/A	N/A	20	News Coverage Positive News Upcoming Earnings Analyst Downgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INTS) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intensity Therapeutics (INTS) Competitors

INTS vs. BYSI, ATYR, GOSS, EDSA, and MCRB

How does Intensity Therapeutics compare to BeyondSpring?

Summary

How does Intensity Therapeutics compare to aTyr Pharma?

Summary

How does Intensity Therapeutics compare to Gossamer Bio?

Summary

How does Intensity Therapeutics compare to Edesa Biotech?

Summary

How does Intensity Therapeutics compare to Seres Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intensity Therapeutics (INTS) Competitors

INTS vs. BYSI, ATYR, GOSS, EDSA, and MCRB

How does Intensity Therapeutics compare to BeyondSpring?

Do analysts rate BYSI or INTS?

Which has more volatility and risk, BYSI or INTS?

Is BYSI or INTS more profitable?

Does the media prefer BYSI or INTS?

Do insiders & institutionals believe in BYSI or INTS?

Which has higher valuation and earnings, BYSI or INTS?

Summary

How does Intensity Therapeutics compare to aTyr Pharma?

Is ATYR or INTS more profitable?

Does the media prefer ATYR or INTS?

Which has more volatility & risk, ATYR or INTS?

Which has better earnings & valuation, ATYR or INTS?

Do institutionals and insiders hold more shares of ATYR or INTS?

Do analysts prefer ATYR or INTS?

Summary

How does Intensity Therapeutics compare to Gossamer Bio?

Which has better earnings and valuation, INTS or GOSS?

Do institutionals and insiders hold more shares of INTS or GOSS?

Is INTS or GOSS more profitable?

Does the media refer more to INTS or GOSS?

Do analysts prefer INTS or GOSS?

Which has more volatility & risk, INTS or GOSS?

Summary

How does Intensity Therapeutics compare to Edesa Biotech?

Which has stronger valuation and earnings, INTS or EDSA?

Do analysts recommend INTS or EDSA?

Does the media refer more to INTS or EDSA?

Which has more volatility and risk, INTS or EDSA?

Is INTS or EDSA more profitable?

Do institutionals and insiders hold more shares of INTS or EDSA?

Summary

How does Intensity Therapeutics compare to Seres Therapeutics?

Is MCRB or INTS more profitable?

Which has more risk & volatility, MCRB or INTS?

Do institutionals and insiders have more ownership in MCRB or INTS?

Do analysts rate MCRB or INTS?

Which has stronger earnings and valuation, MCRB or INTS?

Does the media favor MCRB or INTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools